Milestone Pharmaceuticals Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Milestone Pharmaceuticals Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($11.92M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($12.97M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($20.76M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($9.44M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($9.36M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($10.35M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($15.08M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($16.04M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.95M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($14.56M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($16.65M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($14.01M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($14.23M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | $770.0K | Aug 10, 2022 |
| Q2 | 2021 | Mar 31, 2021 | ($12.51M) | Aug 11, 2021 |
| Q1 | 2022 | Mar 31, 2021 | ($12.51M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($11.98M) | Nov 12, 2021 |
| Q3 | 2020 | Jun 30, 2020 | ($12.98M) | Nov 13, 2020 |
| Q2 | 2021 | Jun 30, 2020 | ($12.98M) | Aug 11, 2021 |
| Q2 | 2021 | Mar 31, 2020 | ($16.34M) | Aug 11, 2021 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($11.83M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($12.53M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($20.52M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($9.62M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($9.66M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($10.48M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($15.36M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($16.44M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($15.50M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($15.03M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($16.81M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($14.05M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($14.27M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | $712.0K | Aug 10, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($12.59M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($12.09M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($13.11M) | Aug 11, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($16.76M) | May 17, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($13.73M) | Nov 13, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($14.33M) | Aug 12, 2020 |